Literature DB >> 26589820

Validation of the Framingham Heart Study and CHARGE-AF Risk Scores for Atrial Fibrillation in Hispanics, African-Americans, and Non-Hispanic Whites.

Eric Shulman1, Faraj Kargoli1, Philip Aagaard1, Ethan Hoch1, Luigi Di Biase1, John Fisher1, Jay Gross1, Soo Kim1, Andrew Krumerman1, Kevin J Ferrick2.   

Abstract

A risk score for atrial fibrillation (AF) has been developed by the Framingham Heart Study and Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)-AF consortium. However, validation of these risk scores in an inner-city population is uncertain. Thus, a validation model was built using the Framingham Risk Score for AF and CHARGE-AF covariates. An in and outpatient electrocardiographic database was interrogated from 2000 to 2013 for the development of AF. Patients were included if their age was >45 and <95 years, had <10-year follow-up, if their initial electrocardiogram was without AF, had ≥ 2 electrocardiograms, and declared a race and/or ethnicity as non-Hispanic white, African-American, or Hispanic. For the Framingham Heart Study, 49,599 patients met inclusion criteria, of which 4,860 developed AF. Discrimination analysis using area under the curve (AUC) for original risk equations: non-Hispanic white AUC = 0.712 (95% confidence interval [CI] 0.694 to 0.731), African-American AUC = 0.733 (95% CI 0.716 to 0.751), and Hispanic AUC = 0.740 (95% CI 0.723 to 0.757). For the CHARGE-AF, 45,571 patients met inclusion criteria, of which 4,512 developed AF. Non-Hispanic white AUC = 0.673 (95% CI 0.652 to 0.694), African-American AUC = 0.706 (95% CI 0.685 to 0.727), and Hispanic AUC = 0.711 (95% CI 0.691 to 0.732). Calibration analysis showed qualitative similarities between cohorts. In conclusion, this is the first study to validate both the Framingham Heart Study and CHARGE-AF risk scores in both a Hispanic and African-American cohort. All models predicted AF well across all race and ethnic cohorts.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26589820     DOI: 10.1016/j.amjcard.2015.10.009

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

2.  Evaluation of Risk Prediction Models of Atrial Fibrillation (from the Multi-Ethnic Study of Atherosclerosis [MESA]).

Authors:  Joshua D Bundy; Susan R Heckbert; Lin Y Chen; Donald M Lloyd-Jones; Philip Greenland
Journal:  Am J Cardiol       Date:  2019-10-10       Impact factor: 2.778

3.  Risk Factors for Symptomatic Atrial Fibrillation-Analysis of an Outpatient Database.

Authors:  Annabelle Santos Volgman; Patrick Dunn; Allison Sundberg; Scott Conard; Pavitra Chakravarty; Zin Htway; Albert Waldo; Christine Albert; Mintu P Turakhia; Gerald V Naccarelli
Journal:  J Atr Fibrillation       Date:  2019-06-30

4.  Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.

Authors:  Renate B Schnabel; Renke Maas; Na Wang; Xiaoyan Yin; Martin G Larson; Daniel Levy; Patrick T Ellinor; Steven A Lubitz; David D McManus; Jared W Magnani; Dorothee Atzler; Rainer H Böger; Edzard Schwedhelm; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-03-17       Impact factor: 4.749

5.  Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation.

Authors:  Lu-Chen Weng; Sarah R Preis; Olivia L Hulme; Martin G Larson; Seung Hoan Choi; Biqi Wang; Ludovic Trinquart; David D McManus; Laila Staerk; Honghuang Lin; Kathryn L Lunetta; Patrick T Ellinor; Emelia J Benjamin; Steven A Lubitz
Journal:  Circulation       Date:  2017-11-12       Impact factor: 29.690

6.  The appropriate use of risk scores in the prediction of atrial fibrillation.

Authors:  Wesley T O'Neal; Alvaro Alonso
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

7.  Performance of Atrial Fibrillation Risk Prediction Models in Over 4 Million Individuals.

Authors:  Shaan Khurshid; Uri Kartoun; Jeffrey M Ashburner; Ludovic Trinquart; Anthony Philippakis; Amit V Khera; Patrick T Ellinor; Kenney Ng; Steven A Lubitz
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-12-09

8.  Trajectories of Risk Factors and Risk of New-Onset Atrial Fibrillation in the Framingham Heart Study.

Authors:  Faisal Rahman; Xiaoyan Yin; Martin G Larson; Patrick T Ellinor; Steven A Lubitz; Ramachandran S Vasan; David D McManus; Jared W Magnani; Emelia J Benjamin
Journal:  Hypertension       Date:  2016-07-11       Impact factor: 10.190

9.  Ethnic and Gender Differences in 10-Year Coronary Heart Disease Risk: a Cross-Sectional Study in Hawai'i.

Authors:  Claire Townsend Ing; Hyeong Jun Ahn; Rachel Kawakami; Andrew Grandinetti; Todd B Seto; Joseph Keawe'aimoku Kaholokula
Journal:  J Racial Ethn Health Disparities       Date:  2020-08-31

10.  A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study.

Authors:  Ingrid E Christophersen; Xiaoyan Yin; Martin G Larson; Steven A Lubitz; Jared W Magnani; David D McManus; Patrick T Ellinor; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-05-17       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.